Utah's Office of Artificial Intelligence Policy (OAIP), acting under statutory authority to grant temporary regulatory relief, authorized health-tech startup Doctronic to test AI-driven prescription renewals. The one-year pilot (October 2025 – October 2026) covers 30-, 60- or 90-day renewals for a formulary of roughly 20-200 non-controlled medications; in Phase 1, every AI-recommended renewal must be reviewed by a licensed physician before it reaches the pharmacy.
Safeguards include identity verification, hard stops preventing dispensation of controlled substances, escalation protocols routing complex cases to human physicians, a requirement that Doctronic carry medical liability insurance covering AI-related risk, and monthly compliance reporting to OAIP.
As of May 2026, OAIP had reported no serious safety incidents, based on just two monthly compliance reports received so far; a Deseret News article cited an earlier validation test in which Doctronic's recommendations matched physicians' treatment plans in 99.2% of 500 urgent-care cases. Independent security researchers identified vulnerabilities in the platform (reported via Telehealth.org), and the American Medical Association's CEO publicly warned about accountability risks when AI makes renewal decisions without direct physician involvement. Rigorous measurement of economic and public-health outcomes is not scheduled until later pilot phases.
Read the full analysis: https://commerce.utah.gov/ai/regulatory-relief/authorized-ai-pilots/doctronic/
Where this practice's information was retrieved from, and when.